Brokerages Anticipate Intellipharmaceutics International Inc. (IPCI) Will Announce Earnings of -$0.04 Per Share

Analysts expect Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) to post ($0.04) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Intellipharmaceutics International’s earnings. The highest EPS estimate is $0.03 and the lowest is ($0.10). Intellipharmaceutics International posted earnings per share of ($0.14) during the same quarter last year, which would indicate a positive year-over-year growth rate of 71.4%. The company is scheduled to announce its next earnings results on Friday, February 9th.

According to Zacks, analysts expect that Intellipharmaceutics International will report full-year earnings of ($0.21) per share for the current fiscal year, with EPS estimates ranging from ($0.31) to ($0.11). For the next financial year, analysts forecast that the firm will report earnings of $0.10 per share, with EPS estimates ranging from ($0.32) to $0.51. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover Intellipharmaceutics International.

Several brokerages have issued reports on IPCI. Zacks Investment Research downgraded Intellipharmaceutics International from a “hold” rating to a “sell” rating in a report on Thursday, September 28th. Mackie raised Intellipharmaceutics International to a “hold” rating and raised their price target for the company from $1.00 to $3.10 in a report on Tuesday, September 26th. ValuEngine downgraded Intellipharmaceutics International from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Finally, Maxim Group cut their price target on Intellipharmaceutics International from $6.00 to $2.00 and set a “buy” rating for the company in a report on Thursday, July 27th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company’s stock. Intellipharmaceutics International currently has an average rating of “Hold” and an average target price of $2.37.

Shares of Intellipharmaceutics International (NASDAQ IPCI) traded up 1.0769% during trading on Friday, reaching $0.9198. 33,326 shares of the company were exchanged. The company has a 50 day moving average price of $1.01 and a 200-day moving average price of $1.64. The stock’s market capitalization is $28.58 million. Intellipharmaceutics International has a one year low of $0.81 and a one year high of $3.35.

A hedge fund recently raised its stake in Intellipharmaceutics International stock. Advisor Group Inc. lifted its position in shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) by 57.7% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 47,409 shares of the company’s stock after buying an additional 17,342 shares during the quarter. Advisor Group Inc. owned about 0.16% of Intellipharmaceutics International worth $100,000 as of its most recent SEC filing. Institutional investors own 3.47% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Brokerages Anticipate Intellipharmaceutics International Inc. (IPCI) Will Announce Earnings of -$0.04 Per Share” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.com-unik.info/2017/10/30/brokerages-anticipate-intellipharmaceutics-international-inc-ipci-will-announce-earnings-of-0-04-per-share.html.

About Intellipharmaceutics International

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.

Get a free copy of the Zacks research report on Intellipharmaceutics International (IPCI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Intellipharmaceutics International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intellipharmaceutics International Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit